Dr. John Cush RheumNow
2 years 4 months ago
Forbes on the future of CAR-T cell therapy - A Gamechanger For Autoimmune Diseases. Innovation, costs, more trials and regulatory differences for autoimmune (vs cancer) patietns? https://t.co/1Yg40HPTzh https://t.co/NqCwEzmZ1g
Dr. Jack Cush reviews the journal reports and articles from this past week on RheumNow.com. The ACR (and Cush) address their new website designed to educate PCPs and APPs - what do you think?
Prof. Feynman ProfFeynman
2 years 4 months ago
There's a huge difference between knowing the name of something and knowing something.
We talk in fact-deficient, obfuscating generalities to cover up our lack of understanding.
NatRevRheumatol NatRevRheumatol
2 years 4 months ago
#JuneIssue | Relapsing polychondritis is challenging to diagnosis owing to overlapping symptoms with other conditions
Learn more about the clinical features and differential diagnoses in this #Review
https://t.co/iXl9rQ0ONS
Dr. John Cush RheumNow
2 years 4 months ago
Kaiser/California EHR study of #SLE pregnancies (2011-2020) - 657 pregnancies in 453 prs; The live birth rate = 74%, 23% w/ Spontaneous Ab, 2% ectopic/molar & <1% stillbirths. Variable outcomes by race & ethnicity, aPL status & nephritis history https://t.co/gvmYpTuFon https://t.co/9TeG8kfLmK
A large, propensity score-matched cohort study shows that metformin use in patients with pre-diabetes significantly lowers the risk of future gout.
Dr. John Cush RheumNow
2 years 4 months ago
JAMA full read comprehensive review of 'Chronic Pruritus' affecting 22%, 1% of all out pt visits
- Dx algorithm
- Pathophys
- Rx options
- Alternative Rx
https://t.co/4sd2HqUX9Y https://t.co/FoVHFnfEPa
Dr. John Cush RheumNow
2 years 4 months ago
Do you have a rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/qvVEUoNYi5 https://t.co/duw6jg5xpp
Dr. John Cush RheumNow
2 years 4 months ago
Hypertension not associated with High NSAID Doses in AxSpA
At the SPARTAN meeting, Dr.Meade-Aguilar reported that amongst axSpA patients receiving NSAIDs, there was no diff in the risk for hypertension when comparing those on high vs. low dose NSAIDs.
https://t.co/UsRfobVHO7 https://t.co/fGj5yO53Yk
Dr. John Cush RheumNow
2 years 4 months ago
Save the date! We are covering #EULAR24! We'll be sharing recaps, videos, and more. https://t.co/vEQUZGAuJe
Dr. John Cush RheumNow
2 years 4 months ago
2 large 48-wk phase 3 trials (Be HEARD I/II) of Bimekizumab vs PBO in moderate-to-severe hidradenitis suppurativa shows BKZ to be safe & significantly effective (48% vs 29% & 52% vs 32%) vs PBO. https://t.co/xPXUd9vHyE https://t.co/uESOGYhAdw
Adam Grant AdamMGrant
2 years 4 months ago
Most leaders value loyalty. Great leaders put a higher premium on integrity.
Loyalty is allegiance to power. You're expected to show deference and follow orders.
Integrity is allegiance to principles. You're expected to challenge orders that violate your mission or values.
A single center study demonstrates that biologic treatment of psoriasis (PsO) significantly reduces the likelihood of psoriatic arthritis (PsA) development; suggesting a role for more aggressive treatment of PsO.
The American College of Rheumatology recently launched Rheumatology for Primary Care, a new resource for primary care physicians (PCP) and advanced practice providers (APP) offering them expanded support and guidance to identify rheumatic diseases in their patients.
